Duplex Shiny App Quantification of the Sepsis Biomarkers C-reactive Protein and Interleukin-6 in a Fast Quantum Dot Labeled Lateral Flow Assay

Overview

Journal J Nanobiotechnology

Publisher Biomed Central

Specialty Biotechnology

Date 2020 Sep 11

PMID 32912236

Citations 11

Authors

Christoph Ruppert

Lars Kaiser

Lisa Johanna Jacob

Stefan Laufer

Matthias Kohl

Hans-Peter Deigner

Affiliations

Soon will be listed here.

Abstract

Fast point-of-care (POC) diagnostics represent an unmet medical need and include applications such as lateral flow assays (LFAs) for the diagnosis of sepsis and consequences of cytokine storms and for the treatment of COVID-19 and other systemic, inflammatory events not caused by infection. Because of the complex pathophysiology of sepsis, multiple biomarkers must be analyzed to compensate for the low sensitivity and specificity of single biomarker targets. Conventional LFAs, such as gold nanoparticle dyed assays, are limited to approximately five targets-the maximum number of test lines on an assay. To increase the information obtainable from each test line, we combined green and red emitting quantum dots (QDs) as labels for C-reactive protein (CRP) and interleukin-6 (IL-6) antibodies in an optical duplex immunoassay. CdSe-QDs with sharp and tunable emission bands were used to simultaneously quantify CRP and IL-6 in a single test line, by using a single UV-light source and two suitable emission filters for readout through a widely available BioImager device. For image and data processing, a customized software tool, the MultiFlow-Shiny app was used to accelerate and simplify the readout process. The app software provides advanced tools for image processing, including assisted extraction of line intensities, advanced background correction and an easy workflow for creation and handling of experimental data in quantitative LFAs. The results generated with our MultiFlow-Shiny app were superior to those generated with the popular software ImageJ and resulted in lower detection limits. Our assay is applicable for detecting clinically relevant ranges of both target proteins and therefore may serve as a powerful tool for POC diagnosis of inflammation and infectious events.

Citing Articles

Optical Bionanosensors for Sepsis Diagnostics.

Derichsweiler C, Herbertz S, Kruss S Small. 2025; 21(8):e2409042.

PMID: 39745136 PMC: 11855245. DOI: 10.1002/smll.202409042.

Recent Progresses in Optical Biosensors for Interleukin 6 Detection.

Majdinasab M, Lamy de la Chapelle M, Marty J Biosensors (Basel). 2023; 13(9).

PMID: 37754132 PMC: 10526799. DOI: 10.3390/bios13090898.

Nanotechnology Applications in Sepsis: Essential Knowledge for Clinicians.

Vasconcelos I, Santos T Pharmaceutics. 2023; 15(6).

PMID: 37376129 PMC: 10302508. DOI: 10.3390/pharmaceutics15061682.

Ultrasensitive and point-of-care detection of plasma phosphorylated tau in Alzheimer's disease using colorimetric and surface-enhanced Raman scattering dual-readout lateral flow assay.

Zhang L, Su Y, Liang X, Cao K, Luo Q, Luo H Nano Res. 2023; 16(5):7459-7469.

PMID: 37223429 PMC: 9971675. DOI: 10.1007/s12274-022-5354-4.

Clinical data mining reveals Gancao-Banxia as a potential herbal pair against moderate COVID-19 by dual binding to IL-6/STAT3.

Luo W, Ding R, Guo X, Zhan T, Tang T, Fan R Comput Biol Med. 2022; 145:105457.

PMID: 35366469 PMC: 8957363. DOI: 10.1016/j.compbiomed.2022.105457.

References

Pfafflin A, Schleicher E . Inflammation markers in point-of-care testing (POCT). Anal Bioanal Chem. 2008; 393(5):1473-80. DOI: 10.1007/s00216-008-2561-3. View

Lim Y, Kim S, Nakayama A, Stott N, Bawendi M, Frangioni J . Selection of quantum dot wavelengths for biomedical assays and imaging. Mol Imaging. 2003; 2(1):50-64. DOI: 10.1162/15353500200302163. View

Lamping F, Jack T, Rubsamen N, Sasse M, Beerbaum P, Mikolajczyk R . Development and validation of a diagnostic model for early differentiation of sepsis and non-infectious SIRS in critically ill children - a data-driven approach using machine-learning algorithms. BMC Pediatr. 2018; 18(1):112. PMC: 5853156. DOI: 10.1186/s12887-018-1082-2. View

Posthuma-Trumpie G, Korf J, van Amerongen A . Lateral flow (immuno)assay: its strengths, weaknesses, opportunities and threats. A literature survey. Anal Bioanal Chem. 2008; 393(2):569-82. DOI: 10.1007/s00216-008-2287-2. View

Povoa P . C-reactive protein: a valuable marker of sepsis. Intensive Care Med. 2002; 28(3):235-43. DOI: 10.1007/s00134-002-1209-6. View

Hu B, Huang S, Yin L . The cytokine storm and COVID-19. J Med Virol. 2020; 93(1):250-256. PMC: 7361342. DOI: 10.1002/jmv.26232. View

Kibe S, Adams K, Barlow G . Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chemother. 2011; 66 Suppl 2:ii33-40. DOI: 10.1093/jac/dkq523. View

Armbruster D, Pry T . Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 2008; 29 Suppl 1:S49-52. PMC: 2556583. View

Taranova N, Berlina A, Zherdev A, Dzantiev B . 'Traffic light' immunochromatographic test based on multicolor quantum dots for the simultaneous detection of several antibiotics in milk. Biosens Bioelectron. 2014; 63:255-261. DOI: 10.1016/j.bios.2014.07.049. View

10.

Driessen R, van de Poll M, Mol M, van Mook W, Schnabel R . The influence of a change in septic shock definitions on intensive care epidemiology and outcome: comparison of sepsis-2 and sepsis-3 definitions. Infect Dis (Lond). 2017; 50(3):207-213. DOI: 10.1080/23744235.2017.1383630. View

11.

Singer M, Deutschman C, Seymour C, Shankar-Hari M, Annane D, Bauer M . The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801-10. PMC: 4968574. DOI: 10.1001/jama.2016.0287. View

12.

Yang Y, Xie J, Guo F, Longhini F, Gao Z, Huang Y . Combination of C-reactive protein, procalcitonin and sepsis-related organ failure score for the diagnosis of sepsis in critical patients. Ann Intensive Care. 2016; 6(1):51. PMC: 4901212. DOI: 10.1186/s13613-016-0153-5. View

13.

Qi X, Huang Y, Lin Z, Xu L, Yu H . Dual-Quantum-Dots-Labeled Lateral Flow Strip Rapidly Quantifies Procalcitonin and C-reactive Protein. Nanoscale Res Lett. 2016; 11(1):167. PMC: 4807186. DOI: 10.1186/s11671-016-1383-z. View

14.

Li J, Macdonald J . Multiplexed lateral flow biosensors: Technological advances for radically improving point-of-care diagnoses. Biosens Bioelectron. 2016; 83:177-92. DOI: 10.1016/j.bios.2016.04.021. View

15.

Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J . Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020; 92(7):814-818. PMC: 7262125. DOI: 10.1002/jmv.25801. View

16.

Herold T, Jurinovic V, Arnreich C, Lipworth B, Hellmuth J, von Bergwelt-Baildon M . Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020; 146(1):128-136.e4. PMC: 7233239. DOI: 10.1016/j.jaci.2020.05.008. View

17.

Fonseca F, Izar M . High-Sensitivity C-Reactive Protein and Cardiovascular Disease Across Countries and Ethnicities. Clinics (Sao Paulo). 2016; 71(4):235-42. PMC: 4825196. DOI: 10.6061/clinics/2016(04)11. View

18.

Soong J, Soni N . Sepsis: recognition and treatment. Clin Med (Lond). 2012; 12(3):276-80. PMC: 4953494. DOI: 10.7861/clinmedicine.12-3-276. View

19.

Deigner H, Kohl M . The molecular sepsis signature. Crit Care Med. 2009; 37(3):1137-8. DOI: 10.1097/CCM.0b013e31819bb705. View

20.

Cozlea D, Farcas D, Nagy A, Keresztesi A, Tifrea R, Cozlea L . The impact of C reactive protein on global cardiovascular risk on patients with coronary artery disease. Curr Health Sci J. 2014; 39(4):225-31. PMC: 3945266. View